Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

NCT00360828 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Principal Investigator left Moffitt and study had low accrual.

Conditions

Astrocytoma
Glioma
Oligodendroglioma

Interventions

DRUG: Irinotecan Hydrochloride (HCI) Treatment
DRUG: Continued Irinotecan Hydrochloride (HCI) Treatment

Sponsor

H. Lee Moffitt Cancer Center and Research Institute